Citations (64)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Hans Tilman Steinmetz, J. Toczek-Thiel, J. Lipke, R. Liersch, A. Sauer, H. Tesch, J. Heßling, U. Totzke & S. Schmitz. (2023) Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survival. Leukemia & Lymphoma 64:8, pages 1476-1479.
Read now
Read now
Aristoteles A N Giagounidis, Ulrich Germing, Sabine Haase & Carlo Aul. (2007) Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes. Therapeutics and Clinical Risk Management 3:4, pages 553-562.
Read now
Read now
Teru Hideshima, Paul G Richardson & Kenneth C Anderson. (2006) Current therapeutic uses of lenalidomide in multiple myeloma. Expert Opinion on Investigational Drugs 15:2, pages 171-179.
Read now
Read now
Articles from other publishers (61)
Benoît Soubise, Yan Jiang, Nathalie Douet-Guilbert & Marie-Bérengère Troadec. (2022) RBM22, a Key Player of Pre-mRNA Splicing and Gene Expression Regulation, Is Altered in Cancer. Cancers 14:3, pages 643.
Crossref
Crossref
Sangeetha Venugopal, John Mascarenhas & David P. Steensma. (2021) Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences. Blood Reviews 46, pages 100735.
Crossref
Crossref
Nicholas C. Brehl. 2020. Rodak's Hematology. Rodak's Hematology
589
602
.
David P. Steensma & Richard M. Stone. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1798
1820.e11
.
Austin G. Kulasekararaj, Olivier Kosmider & Ghulam J. Mufti. 2018. Myelodysplastic Syndromes. Myelodysplastic Syndromes
15
37
.
Marcin Kruszewski, Adriana Czyż, Krzysztof Lewandowski, Monika Prochorec-Sobieszek & Jarosław Czyż. (2016) The patient with 5q minus syndrome and JAK2 V617F mutation with the presence of ringed erythroblasts meeting the criteria of RARS-T effectively treated with lenalidomide – A case report. Acta Haematologica Polonica 47:1, pages 29-32.
Crossref
Crossref
QING NIAN, JIANXIANG CHI, QING XIAO, CHUNMEI WEI, PAUL COSTEAS, ZESONG YANG, LIN LIU & LI WANG. (2015) SPARC ectopic overexpression inhibits growth and promotes programmed cell death in acute myeloid leukemia transformed from myelodysplastic syndrome cells, alone and in combination with Ara-C treatment. Oncology Reports 34:3, pages 1406-1414.
Crossref
Crossref
QING NIAN, QING XIAO, LI WANG, JING LUO, LI-PING CHEN, ZE-SONG YANG & LIN LIU. (2014) SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis. International Journal of Molecular Medicine 33:4, pages 856-862.
Crossref
Crossref
Andrea Kuendgen. (2014) The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q—New prognostic markers are needed. Leukemia Research 38:3, pages 287-288.
Crossref
Crossref
Silvia M. Rojas, María Díez-Campelo, Elisa Luño, Mónica Cabrero, Carme Pedro, Marisa Calabuig, Benet Nomdedeu, Teresa Cedena, Beatriz Arrizabalaga, Marta García, Carlos Cerveró, Rosa Collado, Gemma Azaceta, Mª Teresa Ardanaz, Juan Antonio Muñoz, Blanca Xicoy, Mª José Requena Rodríguez, Joan Bargay, Mª Jesús Arilla Morell, Adriana Simiele & Consuelo del Cañizo. (2014) Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis. Leukemia Research 38:3, pages 304-309.
Crossref
Crossref
Rainer Haas & Ulrich GermingJulie SchanzDetlef Haase. 2014. Novel Insights into Pathophysiology, Diagnostics and Treatment of Myelodysplastic Syndromes. Novel Insights into Pathophysiology, Diagnostics and Treatment of Myelodysplastic Syndromes
48
69
.
David P. Steensma & Richard M. Stone. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1907
1928.e8
.
A Kuendgen, M Lauseker, A F List, P Fenaux, A A Giagounidis, N A Brandenburg, J Backstrom, A Glasmacher, J Hasford & U Germing. (2012) Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia 27:5, pages 1072-1079.
Crossref
Crossref
Aleksandra Butrym, Justyna Dzietczenia & Grzegorz Mazur. (2012) Zespoły mielodysplastyczne niskiego ryzyka z delecją 5q. Acta Haematologica Polonica 43:4, pages 331-335.
Crossref
Crossref
U Germing, M Lauseker, B Hildebrandt, A Symeonidis, J Cermak, P Fenaux, C Kelaidi, M Pfeilstöcker, T Nösslinger, M Sekeres, J Maciejewski, D Haase, J Schanz, J Seymour, M Kenealy, R Weide, M Lübbert, U Platzbecker, P Valent, K Götze, R Stauder, S Blum, K-A Kreuzer, R Schlenk, A Ganser, W-K Hofmann, C Aul, O Krieger, A Kündgen, R Haas, J Hasford & A Giagounidis. (2012) Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study. Leukemia 26:6, pages 1286-1292.
Crossref
Crossref
Maryalice Stetler‐Stevenson, Joseph A. DiGiuseppe & Diane C. Arthur. 2012. Laboratory Hematology Practice. Laboratory Hematology Practice
331
344
.
Ota Fuchs. (2012) Important Genes in the Pathogenesis of 5q- Syndrome and Their Connection with Ribosomal Stress and the Innate Immune System Pathway. Leukemia Research and Treatment 2012, pages 1-14.
Crossref
Crossref
Jacqueline Boultwood, Andrea Pellagatti & James S. Wainscoat. (2012) Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome. Advances in Biological Regulation 52:1, pages 196-203.
Crossref
Crossref
Fabien Le Bras, Marie Sebert, Charikleia Kelaidi, Thierry Lamy, François Dreyfus, Jacques Delaunay, Anne Banos, Michel Blanc, Norbert Vey, Aline Schmidt, Sorin Visanica, Virginie Eclache, Pascal Turlure, Odile Beyne-Rauzy, Agnès Guerci, Alain Delmer, Stéphane de Botton, Delphine Rea, Pierre Fenaux & Lionel Adès. (2011) Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience. Leukemia Research 35:11, pages 1444-1448.
Crossref
Crossref
Rami S. Komrokji & Alan F. List. (2011) Role of Lenalidomide in the Treatment of Myelodysplastic Syndromes. Seminars in Oncology 38:5, pages 648-657.
Crossref
Crossref
David P. Steensma. (2011) Hematopoietic Growth Factors in Myelodysplastic Syndromes. Seminars in Oncology 38:5, pages 635-647.
Crossref
Crossref
Benjamin L. Ebert. (2011) Molecular Dissection of the 5q Deletion in Myelodysplastic Syndrome. Seminars in Oncology 38:5, pages 621-626.
Crossref
Crossref
Joanna Wegrzyn, Jeffrey C. Lam & Aly Karsan. (2011) Mouse models of myelodysplastic syndromes. Leukemia Research 35:7, pages 853-862.
Crossref
Crossref
Cristina Clissa, Carlo Finelli & Antonio de Vivo. (2011) Le sindromi mielodisplastiche: diagnosi, prognosi e terapia. Italian Journal of Medicine 5:2, pages 90-97.
Crossref
Crossref
Alice H Berger & Pier Paolo Pandolfi. (2010) Haplo‐insufficiency: a driving force in cancer. The Journal of Pathology 223:2, pages 138-147.
Crossref
Crossref
Jacqueline Boultwood, Andrea Pellagatti, Andrew N. J. McKenzie & James S. Wainscoat. (2010) Advances in the 5q− syndrome. Blood 116:26, pages 5803-5811.
Crossref
Crossref
Jianghong WangAnthony A. FernaldJohn Anastasi, Michelle M. Le Beau & Zhijian Qian. (2010) Haploinsufficiency of Apc leads to ineffective hematopoiesis. Blood 115:17, pages 3481-3488.
Crossref
Crossref
A Pellagatti, M Cazzola, A Giagounidis, J Perry, L Malcovati, M G Della Porta, M Jädersten, S Killick, A Verma, C J Norbury, E Hellström-Lindberg, J S Wainscoat & J Boultwood. (2010) Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 24:4, pages 756-764.
Crossref
Crossref
Rami S. Komrokji & Alan F. List. (2010) Lenalidomide for Treatment of Myelodysplastic Syndromes: Current Status and Future Directions. Hematology/Oncology Clinics of North America 24:2, pages 377-388.
Crossref
Crossref
David P. Steensma. (2010) ASH 2009 meeting report—Top 10 clinically oriented abstracts in myelodysplastic syndromes. American Journal of Hematology 85:3, pages 196-201.
Crossref
Crossref
Wojciech Gorczyca. 2010. Flow Cytometry in Neoplastic Hematology. Flow Cytometry in Neoplastic Hematology
293
312
.
Jillian L Barlow, Lesley F Drynan, Duncan R Hewett, Luke R Holmes, Silvia Lorenzo-Abalde, Alison L Lane, Helen E Jolin, Richard Pannell, Angela J Middleton, See Heng Wong, Alan J Warren, James S Wainscoat, Jacqueline Boultwood & Andrew N J McKenzie. (2009) A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q– syndrome. Nature Medicine 16:1, pages 59-66.
Crossref
Crossref
Rami S. Komrokji, Jeffrey E. Lancet & Alan F. List. (2010) Lenalidomide in Myelodysplastic Syndromes: An Erythropoiesis-Stimulating Agent or More?. Current Hematologic Malignancy Reports 5:1, pages 9-14.
Crossref
Crossref
Hon Fong L. Mark, Susana C. Raimondi & Robert Sokolic. 2010. Mechanisms of Oncogenesis. Mechanisms of Oncogenesis
89
113
.
Lisa Pleyer, Daniel Neureiter, Victoria Faber & Richard Greil. 2010. Chronic Myeloid Neoplasias and Clonal Overlap Syndromes. Chronic Myeloid Neoplasias and Clonal Overlap Syndromes
153
222
.
Jennifer J. D. Morrissette, Karen Weck & Cherie H. Dunphy. 2010. Molecular Pathology of Hematolymphoid Diseases. Molecular Pathology of Hematolymphoid Diseases
129
152
.
K M Eisenmann, K J Dykema, S F Matheson, N F Kent, A D DeWard, R A West, R Tibes, K A Furge & A S Alberts. (2009) 5q– myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Oncogene 28:39, pages 3429-3441.
Crossref
Crossref
Attilio Orazi & Magdalena B. Czader. (2009) Myelodysplastic Syndromes. American Journal of Clinical Pathology 132:2, pages 290-305.
Crossref
Crossref
B L Ebert. (2009) Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia 23:7, pages 1252-1256.
Crossref
Crossref
Thomas O'Hare, Christopher A. Eide & Michael W. Deininger. 2008. The Biology and Treatment of Cancer. The Biology and Treatment of Cancer
193
221
.
T Tasaka, K Tohyama, M Kishimoto, K Ohyashiki, K Mitani, T Hotta, A Kanamaru, S Okamoto, M Karasawa, A Kimura, M Tomonaga, T Uchiyama & K Ozawa. (2008) Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan. Leukemia 22:10, pages 1874-1881.
Crossref
Crossref
Jelena M. Kao, Alex McMillan & Peter L. Greenberg. (2008) International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes. American Journal of Hematology 83:10, pages 765-770.
Crossref
Crossref
Jacqueline Boultwood & James S. Wainscoat. (2008) Molecular Pathogenesis of the 5q– Syndrome: The Role of RPS14 in Pathogenesis and SPARC in the Hematologic Response to Lenalidomide. Clinical Leukemia 2:3, pages 182-186.
Crossref
Crossref
Andrea Pellagatti, Eva Hellström-Lindberg, Aristoteles Giagounidis, Janet Perry, Luca Malcovati, Matteo G. Della Porta, Martin Jädersten, Sally Killick, Carrie Fidler, Mario Cazzola, James S. Wainscoat & Jacqueline Boultwood. (2008) Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes. British Journal of Haematology 142:1, pages 57-64.
Crossref
Crossref
Richard Byers & Eleni Tholouli. (2008) Molecular diagnostics in haematopathology. Diagnostic Histopathology 14:5, pages 223-235.
Crossref
Crossref
Mikkael A. Sekeres & Alan F. List. (2008) Active Treatment Strategies Improving Outcomes in Patients with Myelodysplastic Syndromes with the Deletion 5q Abnormality. Clinical Leukemia 2:1, pages 28-33.
Crossref
Crossref
Kevin M. Shannon & Michelle M. Le Beau. (2008) Hay in a haystack. Nature 451:7176, pages 252-253.
Crossref
Crossref
Detlef HaaseUlrich GermingJulie SchanzMichael PfeilstöckerThomas NösslingerBarbara HildebrandtAndrea KundgenMichael LübbertRegina KunzmannAristoteles A. N. GiagounidisCarlo AulLorenz TrümperOtto KriegerReinhard StauderThomas H. MüllerFriedrich Wimazal, Peter Valent, Christa Fonatsch & Christian Steidl. (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:13, pages 4385-4395.
Crossref
Crossref
Jacqueline Boultwood, Andrea Pellagatti, Helen Cattan, Charles H. Lawrie, Aristoteles Giagounidis, Luca Malcovati, Matteo G. Della Porta, Martin Jädersten, Sally Killick, Carrie Fidler, Mario Cazzola, Eva Hellström-Lindberg & James S. Wainscoat. (2007)
Gene expression profiling of CD34
+
cells in patients with the 5q− syndrome
. British Journal of Haematology 139:4, pages 578-589.
Crossref
Crossref
Lars NilssonPatrik EdénEleonor OlssonRobert MånssonIngbritt Åstrand-GrundströmBodil StrömbeckKim Theilgaard-MönchKristina AndersonRobert HastEva Hellström-LindbergJan SamuelssonGösta Bergh, Claus Nerlov, Bertil JohanssonMikael SigvardssonÅke BorgSten Eirik W. Jacobsen. (2007) The molecular signature of MDS stem cells supports a stem-cell origin of 5q− myelodysplastic syndromes. Blood 110:8, pages 3005-3014.
Crossref
Crossref
Harold J. Olney & Michelle M. Le Beau. (2007) Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. Leukemia Research 31:4, pages 427-434.
Crossref
Crossref
Aristoteles A. N. Giagounidis, Sabine Haase, Michael Heinsch, Gudrun Göhring, Brigitte Schlegelberger & Carlo Aul. (2006) Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Annals of Hematology 86:2, pages 133-137.
Crossref
Crossref
Alan F. List. (2017) Evolving Applications of Lenalidomide in the Management of Anemia in Myelodysplastic Syndromes. Cancer Control 13:4_suppl, pages 12-16.
Crossref
Crossref
David P. Steensma. (2006) Are myelodysplastic syndromes “cancer”?. Leukemia Research 30:10, pages 1227-1233.
Crossref
Crossref
Stephen D. Nimer. (2006) Clinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5q. Journal of Clinical Oncology 24:16, pages 2576-2582.
Crossref
Crossref
W H Matsui, R A Brodsky, B D Smith, M J Borowitz & R J Jones. (2006) Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia 20:3, pages 458-462.
Crossref
Crossref
Aristoteles A.N. Giagounidis, Ulrich Germing & Carlo Aul. (2006) Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid Malignancies. Clinical Cancer Research 12:1, pages 5-10.
Crossref
Crossref
H. J. Deeg, D. T. Bowen, S. D. Gore, T. Haferlach, M. M. Le Beau & C. NiemeyerPhilip Nivatpumin & Steven D. Gore. 2006. Hematologic Malignancies: Myelodysplastic Syndromes. Hematologic Malignancies: Myelodysplastic Syndromes
111
121
.
A. A. N. Giagounidis, U. Germing, C. Strupp, B. Hildebrandt, M. Heinsch & C. Aul. (2005) Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Annals of Hematology 84:9, pages 569-571.
Crossref
Crossref
Stefan Faderl & Hagop M Kantarjian. (2005) Drug Insight: emerging new drugs in the treatment of myelodysplastic syndromes. Nature Clinical Practice Oncology 2:7, pages 348-355.
Crossref
Crossref
Aristoteles A. N. Giagounidis, Sabine Haase, Ulrich Germing, Brigitte Schlegelberger, Ludwig Wilkens, Guntram Büsche, Hans H. Kreipe, Jochen Wysk, Karl-Heinz Grips, Ulrich Grabenhorst, Frank Rothmann, Michael Lübbert, Arnold Ganser, Manuel Aivado, Michael Heinsch & Carlo Aul. (2005) Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31–q33 with a combination of all-trans-retinoic acid and tocopherol-α: a phase II study. Annals of Hematology 84:6, pages 389-394.
Crossref
Crossref